News from NIH: ME/CFS Webinar - October 17, 2019

Dolphin

Senior Member (Voting Rights)
From October 9 email:

We request your participation in a webinar about updates on NIH’s efforts to advance research on ME/CFS. The webinar will be held on October 17, 2019, 3:00 pm until 4:00 pm ET. Our guest speaker will be Steve Roberds, Ph.D., Chief Scientific Officer at the Tuberous Sclerosis Alliance, who chaired the NANDS Council Working Group for ME/CFS Research. The full text of the Working Group’s report can be found here: https://www.ninds.nih.gov/sites/def...l_working_group_for_mecfs_research_508c_0.pdf


Please note that this call will be conducted via WebEx.


Click here to join the webinar https://nih.webex.com/mw3300/mywebe...06hY-MHD1Xu5sq8wfpqLyW8z3ox84FnzZXim3HKMNOQ2&


1-650-479-3208 ACCESS CODE 625 658 653

*** For those joining the webinar without the WebEx link, the password is 1234 to join***


Thank you in advance for your participation and we look forward to an engaging, thoughtful, and productive conversation.


Regards,

The Trans-NIH ME/CFS Working Group
 
Dr. Avi Nath: Yes, thanks Vicky. So we continue to make steady progress in enrollment and studying the ME/CFS patients in the intramural program. So currently for Visit 1, we've had a total of 48 individuals that include the healthy volunteers and the patients. And then we've had 13 for the second visit which also includes roughly half and half of the patients and healthy volunteers.

We've had to bring back some of the patients after Visit 1 because we added a number of additional tests. So that involved an extra visit, but that is also almost being finished now. So we have another six that are scheduled for Visit 2. And so I think we're doing well with the, as far as recruitment is concerned. And we've collected a lot of data. We started analyzing some of these things to make sure that all the tests that we were doing are ones that we want to take forward or things that are not going to reveal much information, we should drop them out and try to see how we can optimize the number of things that are being done. So that's where we stand currently. Thanks

In case anyone else was curious. I believe they are going for 100 patients total, so probably less than 50% for part 1 and 15% done for part 2.
 
Last edited:
Did they mention how far along the intramural study was? I believe it started recruiting in 2016 and were fast approaching 2020.
They have been calling for help with recruitment for patients and healthy controls which is a free thing people can do to help the process e.g. highlight on social media.
 
Last edited:
Did the NIH indicate in the call whether they'd be following the recommendations of the NANDS report on ME?

From my very sparse notes - in Sept, the Trans-NIH ME/cfs Working Group reviewed the report and categorized the recommendations (things in progress, short-term, long-term).
Some "in progress" items include:
encourage research topics,
general outreach (though the way they talked about that sounded to me as though their current actions are solely responses to requests for info rather than a concerted effort to spread the word/educate),
outreach to scientific endeavours such as InvestInME and other conferences - material on ME will be prepared to provide for NINDS to display at conference exhibits,
partnering with SolveME re its registry and with Columbia about its research app,
implementing GUIDS (to ensure that studies aren't always tapping the same cohort).
Short-term:
set up an inter-agency working group
coordinate research on overlapping conditions.
Re strategic planning
identify gaps,
strengthen ongoing activities,
develop a process for generating a strategic plan (this makes it sound as though the development of the plan is not happening soon --- surprised?)....

The link to the transcript and webcast should be posted here
https://www.nih.gov/mecfs/events
probably by end of Oct 2019.
 
Develop a process for generating a strategic plan... Sigh. A process??

It felt as though they were going to develop a plan, to develop a plan, for developing the plan, to make a plan, to generate a plan that may end up working on a strategic plan. (Either that or I was not hearing that they feel a sense of urgency....)
 
Last edited:
Develop a process for generating a strategic plan... Sigh. A process??
gpg3k75.jpg
 
Read the transcript: mostly the NINDS council report implementation seems to me to be based on a lot of good things, but none of them is game-changing.

Even so, a few things that came up caught my eye:

1. Funding, including possible set-aside funding
2. A new biobank of mecfs samples, available to all
3. Autoimmune diseases and chronic infection can be behind even well-diagnosed mecfs.

1. Set-aside funding?
Claudia Carrera question
...at the September NANDS Council meeting we heard that the council had approved program announcements for ME/CFS all the way back in May and so I'm really glad to see that those are you know that the implementation is in progress, but I'm wondering [when]. And I also am interested in knowing .. if there would be guaranteed funding included, and how much it would be.

Vicky Whittemore["not set-aside but special review, happening asap"]
they're program announcements with special review, which means there is not set-aside funding so there's not specific funding associated with those PARs. It was a way to stimulate research as well as to direct grants to the ME/CFS Special Emphasis Panel because we're finding that ME/CFS grants were being reviewed in other study sections that really did not have the specific expertise. So they are in process.

You can imagine it takes a lot to coordinate input from 24 different Institutes, Centers and Offices to put one of these PARs in place. So the concept was approved in May and we're close to submitting them for review here at NIH and I can't guarantee when they will come out because that really is dependent on the review process in the Office of Extramural Research, so we are working to feverishly to get them out and we hope they'll hopefully come out as soon as possible.

There was some discussion of set-aside again later, but nothing that gave me much hope.

2. NIH Biobanking and Solve patient registry

Biobanks help draw new researchers into the field and can standardise samples.

Dr Steve Roberds
Sometimes barriers to getting new investigators in a field as it can be that they don't have access to the same samples or they don't have access to the patients because those are with the people who have always been in the field, so we felt that it was really important to emphasize that NIH take actions to ensure that there are wide access to biosamples collected from people with ME/CFS so that researchers across the country and across the world can do novel and innovative research, that data are collected in consistent ways so that you can compare data from one study to another

Vicky Whittemore
We have an ME/CFS biorepository in place at our contract site which we call BioSEND. It's a biorepository that is located at Indiana University and we have specimens there from the CFI funded study [Mady Hornig (PI), Ian Lipkin] and we're just in the process of adding the clinical data and will very soon make those biospecimens available to the research community and we also have a proposed pilot to add additional biospecimens that we're working on right now that will greatly expand the number of biospecimens that are in BioSEND and will be available to investigators.
Correction: the section in bold, a comment in square brackets added by me, originally said [run by Ian Lipkin] but I want to make clear that Mady Hornig was the PI for the CFI-funded projects at Columbia, including collecting the samples. Credit where credit is due. My apologies to Mady for this omission.

US Brain biobank
VW
The neuro-related Institutes at NIH came together and have what they call NeuroBioBank, which is actually several different brain banks and banking facilities that are funded through contracts where individuals can donate tissues at the time of surgery or at the time of death and so this is a resource to that we're working with the nonprofit organizations to get the word out about the availability of this NeuroBioBank and we currently do have two brains from individuals with ME/CFS who were donated at the time of their deaths that are available for research and hope to expand that as well.

Patient registry
VW
We're partnering with Solve ME/CFS Initiative to support the development of their registry, patient registry, and a research app that's being developed by Columbia University through their funded Center, ME/CFS Center,

3. Autoimmune diseases and chronic infection can be behind even well-diagnosed mecfs.
Actually, I thought the most interesting comment in the whole call was this, from Walter Koroshetz. He said that it appears that the NIh intramural study (with it's best-in-world diagnostic capacity) has found autoimmune disease and chronic infection in people who otherwise appear to definitely have mecfs:

but we know say from the clinical study at NIH, it's incredibly important to identify other disorders that have a known pathophysiology but can present with symptoms of ME/CFS. Some of the discoveries the Clinical Center we're finding underlying diseases in people who had ME/CFS and were unknown to have these other disorders, oftentimes the autoimmune or chronic infections.
 
Last edited:
Read the transcript: mostly the NINDS council report implementation seems to me to be based on a lot of good things, but none of them is game-changing.

Even so, a few things that came up caught my eye:

1. Funding, including possible set-aside funding
2. A new biobank of mecfs samples, available to all
3. Autoimmune diseases and chronic infection can be behind even well-diagnosed mecfs.

1. Set-aside funding?
Claudia Carrera question

Vicky Whittemore["not set-aside but special review, happening asap"]


There was some discussion of set-aside again later, but nothing that gave me much hope.

2. NIH Biobanking and Solve patient registry

Biobanks help draw new researchers into the field and can standardise samples.

Dr Steve Roberds


Vicky Whittemore


US Brain biobank
VW

Patient registry
VW


3. Autoimmune diseases and chronic infection can be behind even well-diagnosed mecfs.
Actually, I thought the most interesting comment in the whole call was this, from Walter Koroshetz. He said that it appears that the NIh intramural study (with it's best-in-world diagnostic capacity) has found autoimmune disease and chronic infection in people who otherwise appear to definitely have mecfs:

did he expand on what autoimmune diseases and especially what chronic infections they had found?

It would be useful to know as outside of the NIH I doubt many of us are getting tested for these things.
 
Some of the discoveries the Clinical Center we're finding underlying diseases in people who had ME/CFS and were unknown to have these other disorders, oftentimes the autoimmune or chronic infections.
Mass misdiagnosis was specifically warned about when the BPS shift happened. It did not take more than a minimal effort to understand that it would be an inevitable consequence. We even know it happens both ways and it would not be particularly surprising if double-digit % of those diagnosed with ME actually have an alternative explanation, maybe more than one subset.

Can that lead to some action? Hate pwME or not, those other diseases are definitely clear iatrogenic harm when they are missed because of discrimination directed against pwME, predictable and predicted. All the things mentioned are good, but they need to happen at 100x the scale and 100x the urgency.

Every step forward validates that the denial has to stop and work has to begin in earnest. So what's the hold? Liability? Is that it? Just unable to move forward because of the can of worms it will open up? It will happen anyway, refusing to act now only compounds on that failure, might as well rip the band-aid and deal with the consequences.
 
If I remember right, these patients were "well diagnosed" by ME experts.
Doubtful that ME experts would be knowledgeable enough in all those other conditions yet. At least not without much more significant clinical expertise and data are built, with the noise brought down to a minimum and the field instead focused on the real issues that affect ME patients. If it happens with specialists, imagine what else slips through on the BPS side and in the whole of clinical practice. I'm actually curious who in the latter two would do better. I wouldn't bet with any certainty.

But my point was generally about the broader population, how many diagnosed with ME have a condition that medicine can treat or at least provide basic support for. If a sample of carefully vetted patients has a significant %, it's likely even higher in the entire ME population.

That's horrible. It means we know there are people that medicine can significantly help but are denied that help because of mass confusion about how to handle complex illness that we can't yet reliably diagnose. I don't understand how it's ethical to continue this practice. I certainly strongly object to it and if it meant anything I would complain about it but nobody in a position to make a difference seems to care yet.
 
Mass misdiagnosis was specifically warned about when the BPS shift happened.
I think Koroshetz is referring to something rather different. The key point is that here are people who meet the criteria for me/cfs, appear to have me/cfs, but deep exclusionary diagnosis during a week-long in-patient admission at what is probably the best diagnostic facility in the world (the NIH clinical centre at Bethedsa) showed that they have other disorders that present as mecfs. I think Koroshetz was implying we might be able to learn from this e.g do they have some shared pathophysiology with mecfs ?

This is different from missing clear alternative diagnoses, of which there are a broad range, including thyroid issues, depression, cancer, rheumatoid arthritis, hepatitis C and anaemia (I assume that you are referring to Simon Wessely's exhortation not to waste much time on looking for alternative causes of fatigue).
 
Last edited:
Back
Top Bottom